Resistance to Aspirin and/or Clopidogrel Among Patients With PAD.
NCT ID: NCT00262561
Last Updated: 2014-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
263 participants
INTERVENTIONAL
2006-01-31
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main hypothesis is that high platelet activity at the beginning of the study is associated with a higher risk of atherothrombosis. Follow up time is 5 years.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
NCT02217501
Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.
NCT01011257
Platelet Reactivity in PAD Undergoing Percutaneous Angioplasty
NCT04165629
Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction
NCT00714961
Clopidogrel/Aspirin Interaction Study
NCT01102439
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Phenomena of 'resistance' to these drugs have been described by numerous investigators. Essentially resistance means that the effect of the drug described is less than expected or missing, as measured by various laboratory methods. We do not know which way resistance is best described, but it has been described that patients who are 'resistant' to either drug are less protected against future heart attacks or strokes.
Main objectives:
* To measure the activity of platelets in these patients during aspirin treatment.
* To measure the activity of platelets in a minor population of these patients during clopidogrel treatment.
* To evaluate the prognostic significance of resistance to aspirin in these patients.
Methods:
Platelet activity is measured by the PFA-100 (Dade Behring) and by traditional turbidimetric aggregation.
Endpoints:
Myocardial infarction, unstable angina, cerebral infarction, transitory cerebral ischaemia, sudden deterioration of symptoms, percutaneous or surgical vascular intervention, amputation, death.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aspirin
All participants get Aspirin, and platelet reactivity measurements are performed.
Aspirin
The effect of Aspirin on platelet function was assessed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aspirin
The effect of Aspirin on platelet function was assessed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years
* For fertile women: Use of safe contraception (intrauterine contraceptive device, the pill, hormonal skin patches, progestogen injections, progestogen implant, vaginal ring)
Exclusion Criteria
* Known bleeding disorder
* Platelet count \< 140 mia/L or \> 400 mia/L
* Intake of NSAID's, SSRI's or Dipyridamol within the preceding 14 days
* Not radically treated gastrointestinal ulceration within the last 6 month
* Greater surgical procedures performed within the last 3 month
* Severe renal disease
* Severe hepatic disease
* Breast feeding
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danish Heart Foundation
OTHER
Aalborg University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Esben Hjorth Madsen
M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nils Johannesen, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Vascular Surgery, Aalborg Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Vascular Surgery, Aalborg Hospital
Aalborg, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-003844-68
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.